Martínez A, Martínez-Ramirez M, Martínez-Caballero D, Beneit P, Clavel J, Figueroa G, Verdú J
Servicio de Medicina Nuclear, Hospital Universitario San Juan de Alicante, Alicante, España.
Servicio de Medicina Nuclear, Hospital Universitario San Juan de Alicante, Alicante, España.
Rev Esp Med Nucl Imagen Mol. 2017 Jan-Feb;36(1):13-19. doi: 10.1016/j.remn.2016.05.004. Epub 2016 Jul 13.
Radioimmunotherapy (RIT) is one of the therapies directed against molecular targets in non-Hodgkin's lymphoma (NHL).
To evaluate the positioning, safety, and effectiveness of RIT with 90Y-Ibritumomab in NHL patients.
A retrospective study was conducted on patients with NHL who received RIT with 90Y-Ibritumomab. An evaluation was made of the concordance with clinical guidelines, toxicity as rated by the Common Terminology Criteria for Adverse Events (CTCAE), and effectiveness was assessed based on response to treatment, overall survival (OS), and progression-free survival (PFS).
RIT was requested in 26 patients, of whom 21 (11 women, mean age 56±10 years) were included in the study, with the following distribution: Follicular NHL, 67%, Mantle NHL, 14%, Diffuse large B-cell NHL, 9.5%, and Transformed NHL 9.5%. Twelve patients with refractory NHL, 7 for consolidation response, and 2 transplant conditioning, were treated. Adverse effects were observed in 71% of patients, which were usually manageable and transient, and with the most common being thrombocytopenia. At 3-4 months, overall response rate was 76.2% (71.4% complete and 4.8% partial response), and 19% had progression of disease. With a median follow up of 70 months, the OS was 96±8 months, and the PFS was 54±11 months.
RIT showed a moderate correlation with clinical guidelines, and is probably underused. Adverse effects were common, mild, and manageable. The data show a high complete response rate and an increase in the OS and PFS.
放射免疫疗法（RIT）是针对非霍奇金淋巴瘤（NHL）分子靶点的治疗方法之一。
评估90Y-伊布替尼单抗放射免疫疗法在NHL患者中的定位、安全性和有效性。
对接受90Y-伊布替尼单抗放射免疫疗法的NHL患者进行回顾性研究。评估与临床指南的一致性、按照不良事件通用术语标准（CTCAE）分级的毒性，并根据治疗反应、总生存期（OS）和无进展生存期（PFS）评估有效性。
26例患者要求进行放射免疫疗法，其中21例（11名女性，平均年龄56±10岁）纳入研究，分布如下：滤泡性NHL，67%；套细胞NHL，14%；弥漫性大B细胞NHL，9.5%；转化型NHL，9.5%。12例难治性NHL患者、7例用于巩固反应的患者和2例移植预处理患者接受了治疗。71%的患者观察到不良反应，通常可控制且为短暂性，最常见的是血小板减少症。在3至4个月时，总缓解率为76.2%（完全缓解率71.4%，部分缓解率4.8%），19%的患者疾病进展。中位随访70个月，总生存期为96±8个月，无进展生存期为54±11个月。
放射免疫疗法与临床指南显示出中等相关性，可能未得到充分利用。不良反应常见、轻微且可控制。数据显示完全缓解率高，总生存期和无进展生存期增加。
